L-Theanine COA Checklist for Ingredient Buyers

Quick Answer

A certificate of analysis for L-theanine only supports a release decision when the lot number, the assay basis, the analytical method and the identity evidence line up. A headline such as “98% by HPLC” answers none of those questions by itself: the figure may be a release minimum or a typical value, it may be calculated on a dried basis, and a routine non-chiral method does not separate the L form from D-theanine.

Before approving a supplier, ask for the current lot COA, the assay basis and method, a separate identity result such as specific rotation or a chiral test, and the source route. Then check that the batch report matches the sample label, the purchase order and the material that reaches your dock.

The COA line that sounds complete but is not

“L-theanine, 98% by HPLC” is the line that tends to catch the eye in a quote. QA needs the missing details. The result may be calculated on dried powder or on the material as received. It may come from a lot already sold, or be a typical value. And the method may not separate the L form from D-theanine. That is why a buyer should pause before putting the number into a purchase spec. Check the identity, grade and batch across the quote, sample label, COA and order. If the listing describes tea extract but the quote is for isolated L-theanine, ask the supplier to resolve it before sampling.

The TGA table is a useful example of how a percentage belongs with its test conditions: “L-Theanine ≥98 %” sits beside separate identity and control tests. That threshold is for its Australian listed-medicine context. Taiwan’s food-additive standard, by comparison, specifies 98.0–102.0% on a dried basis and gives separate identification criteria. A buyer should not copy either limit into a global purchase spec without checking the market and method. Both references make the same practical point: the assay headline is only one piece of a release decision.[1,2]

Confirm the lot before debating its purity

CAS 3081-61-6 is a good first filter. It will catch some listing errors, but it cannot tell you whether the powder in a sample jar is the same grade that will be packed for the order. Follow the material through its paperwork: exact name, product code, manufacturing site and lot number. A COA headed “L-theanine” with no batch identifier may be a template or old sample; it is not enough to release a new delivery. Ask the supplier to issue a lot-specific report or identify the exact lot available for shipment.

A useful reference specification treats identification and assay as separate rows. The TGA method includes IR absorption and comparison of the HPLC retention time with a reference; assay and specific rotation are listed separately. In other words, a peak at the expected retention time is not the same finding as a quantified assay, and neither alone covers every identity question. Confirm which tests the supplier actually runs on release, then align them with the version of the method your quality group approved.[1]

Ask what reference material the laboratory used, whether the method suits the supplied matrix, and whether the report covers the exact lot. A typical specification, sample COA or previous-batch report can screen a supplier, but does not establish the result of a future lot.

Read the 98% result in context

Take two offers: one says “98% minimum,” the other “99% purity.” The second looks better in a spreadsheet, but the comparison is empty until both sellers define their numbers. Is the 98% a release floor and the 99% a typical batch result? Are they both calculated on dried basis? Taiwan’s food-additive standard specifies a 98.0–102.0% range on dried basis. That upper value belongs to the method and reporting convention; it does not mean more than 100% of the powder’s mass is theanine.[2,3]

Put the basis in the RFQ. Ask whether the reported figure is “not less than” a limit or a two-sided range, whether it is as-is or dried basis, and for the actual result on the offered lot. If the answer is dried basis, request the lot’s moisture or loss-on-drying value too; otherwise the number cannot be reconciled to material as received. When suppliers use different assay methods, ask their QA teams for a method comparison before treating the values as interchangeable.

“HPLC” by itself is a technique name, not a transferable method. Two labs may prepare the sample differently or calculate the peak differently. Ask for the method number or a summary naming its standard and reporting basis. For an outside report, check the lab, report number, test date and sample identifier.

Assay and L-form composition are different questions

There are two separate questions in the words “98% L-theanine”: how much theanine the assay reports, and how the method distinguishes the L-form from its mirror image, D-theanine. A routine non-chiral HPLC method can report a theanine peak without resolving those forms. Researchers have published methods that do separate and quantify the enantiomers, using either chiral derivatization or a chiral stationary phase.[4,5] If the L-form ratio matters to your product specification, ask for the test name and result. A high assay from a non-chiral method does not answer that question by itself.

Specific rotation is often the practical first screen, and the conditions are part of the result. TGA’s guideline cites +7.7° to +8.5°; Taiwan’s standard gives the same range with its sample preparation.[1,2] A supplier who sends only “+8.1°” has left out the information needed to compare it with either reference. Rotation can flag a sample that behaves unexpectedly. It is not, without a validated relationship, a percentage of D-theanine. If a buyer needs that limit, the RFQ should ask for chiral separation and a reported enantiomeric result.

Neither route label is a quality grade. “Fermentation” does not automatically mean cleaner, and “synthetic” does not, on its own, say that the product is racemic. The distinction worth following is what the supplier’s process and dossier actually establish for the material you intend to buy. FDA’s inventory contains notices for particular L-theanine materials and processes, including a defined E. coli fermentation product and chemically synthesized material. Its “no questions” response is tied to a notifier’s conclusion and stated uses; it is not a general approval that transfers to every producer or finished product.[6,7] Ask for the source route and process-related quality controls, then judge the evidence against your own use.

Read the COA as a lot record

Start the COA check by matching identifiers, not scanning for green “Pass” cells. Does the supplier name and manufacturing site match the quote? Is the product code the same on the sample label, COA and specification? Do grade and lot numbers agree? A listing that calls the material “green-tea L-theanine 98%” and a quote for “synthetic L-theanine 99%” may refer to different grades even if both show CAS 3081-61-6. Ask whether you are buying an isolated compound, a standardized extract or a premix, and request the carrier or matrix information when relevant.

Some supplier PDFs are specifications dressed up as COAs: they list limits, then mark each row “Pass,” but show no measured result. That may be adequate for an early screen; it is not lot-release evidence. When QA’s requirement is an assay on a dried basis, the batch report should show the lot result and enough same-lot moisture data to reconcile it. If an external laboratory performed the analysis, ask for the report reference and sample identifier. A document is useful only when your team can connect its numbers to the material being received.

There is no reason to test every possible attribute on every order. First ask where the ingredient goes and what can go wrong there. A powder for a dry capsule has different handling needs from one going into a flavored drink. Identity and assay normally anchor the material check; chiral composition, water, pH, route-related residues, elemental contaminants or microbiology may matter depending on process and market. QA should set the limits with regulatory colleagues. A customer spec or listed-medicine guideline can be useful evidence, but it is not automatically the governing rule for another product category.

Ask about the route and process controls

The production route helps decide which records deserve attention. For fermentation, QA may need the organism description, a GMO statement if the destination requires one, and information on purification, crystallization and microbial controls. For a synthetic material, the relevant questions concern route inputs and residuals and how they are controlled. Buyers do not need a proprietary recipe. They need to know which route-linked risks are covered by the supplier’s release tests and supporting records.

FDA’s GRN 1311 response is a useful example of process-specific documentation. The record names the notifier’s E. coli strain, explains the production process and identifies the food uses under review. FDA wrote that it had “no questions at this time” about that notifier’s GRAS conclusion.[6] The scope is narrow by design: it does not establish how a different supplier makes theanine or whether that producer’s material fits the same intended use. When a listing says “FDA approved,” ask for the notice number and read the actual letter. The inventory identifies the notifier and material more clearly than a badge does.[7]

Name the destination early. “Food grade” says little about whether the documents cover the exact use you plan in the United States, Australia or another market. Likewise, a facility registration does not settle the status of an ingredient in a finished product. Give the actual material, product category and intended use to regulatory colleagues while the supplier is still quoting. It is easier to resolve a documentation gap before committing to a batch than after it has arrived.

What the marketplace page can tell you

Between the sample and the first bulk order

The supplier sample is not only a chance to try the powder. It also shows whether the supplier can work to your specification. Send the requirement before asking for a sample; otherwise the seller may choose an available grade that is easy to ship but not the one your line needs. Ask for the current lot COA and the proposed route statement with the quotation. Get the sample source, pack, lead time and delivery basis in writing too. If a production lot has not yet been selected, ask which tests will be repeated on that lot and make those tests a release condition.

At goods-in, separate the paperwork check from the lab check. First record the product code, batch number and seal condition from the container. Compare that lot number with the COA before sending powder for analysis. If the numbers differ, hold the material and ask the supplier’s quality contact for the report that belongs to this batch. A passing assay for a previous lot cannot release the drum at your dock. Once the identity chain is clear, test the attributes in the approved specification. QA may choose independent confirmation for a new supplier or an unfamiliar method. File that result next to the supplier’s report. If they disagree, check the sample preparation and reference standard before deciding whether the lot meets the release limit.

Formulation testing is a separate decision. A beverage team may run the sample at its planned concentration and check whether it disperses as expected or changes the drink’s taste and clarity. A capsule team will care about how the blend moves through its own filling equipment. Neither result says whether the raw material is L-theanine; that belongs to the identity and assay checks. Record the trial lot and the conditions used. If a future offer changes grade, source route or matrix, the old process result may no longer be relevant, so QA and formulation should review it before adopting the substitute.

Give QA room to set the acceptance limits

Quotes become comparable only when they cover the same material. Specify isolated L-theanine, standardized extract or premix, plus the application and destination. State the assay basis and method, identity tests, and any rotation or chiral requirement. Add other limits your QA team has approved. Ask for the route, lot COA, pack size, sample source, quantity, delivery terms and change-notification practice. If your team has not set a limit, ask what the supplier can support; do not inherit a sales-page number by default.

Keep assay and L-form evidence on separate lines in the spec. For example: “Assay: ≥[QA limit], [method], [as-is or dried basis]”; “L-form check: [rotation conditions or chiral method and limit].” The bracketed parts need decisions from your quality group. A test that fits one analytical method may not transfer to another lab, so settle the method and limit before the RFQ becomes the purchase-order spec.

Release the material you actually qualified

At release, QA should be able to point to the approved spec and the matching batch record. If assay basis, lot identity or a required L-form result is missing, hold the material while the supplier closes that specific gap. Once approved, file the record against one grade and product code. The next purchase then starts with the same requirement; it does not depend on remembering which “98%” listing was checked the first time.

References

1. Therapeutic Goods Administration, Australia. “Theanine: Compositional Guideline.” https://www.tga.gov.au/resources/resources/compositional-guidelines/theanine
2. Taiwan Food and Drug Administration. Food Additives Standards, §09001 L-Theanine. https://www.fda.gov.tw/tc/includes/GetFile.ashx?id=f638422272414747340
3. U.S. Pharmacopeia–Food Chemicals Codex. “l-Theanine.” https://doi.usp.org/USPFCC/FCC_F102529_05_01.html
4. Zhao et al. “Analysis of derivatized and underivatized theanine enantiomers by high-performance liquid chromatography/atmospheric pressure ionization-mass spectrometry.” PubMed. https://pubmed.ncbi.nlm.nih.gov/14755608/
5. “Separation and quantification of theanine enantiomers using high performance liquid chromatography coupled with chiral derivatization.” PubMed. https://pubmed.ncbi.nlm.nih.gov/18161325/
6. U.S. FDA. GRAS Notice 1311 Agency Response Letter: L-theanine produced by E. coli CICC 11189s. https://www.fda.gov/media/195022/download
7. U.S. FDA. GRAS Notice Inventory: L-theanine, including GRNs 209, 501, 338, 1311 and others. https://hfpappexternal.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&search=l-theanine